All Stories

  1. Presynaptic and Postsynaptic Mesolimbic Dopamine D3 Receptors Play Distinct Roles in Cocaine Versus Opioid Reward in Mice
  2. Dual DAT and sigma receptor inhibitors attenuate cocaine effects on nucleus accumbens dopamine dynamics in rats
  3. Modafinil, an atypical CNS stimulant?
  4. An FSCV Study on the Effects of Targeted Typical and Atypical DAT Inhibition on Dopamine Dynamics in the Nucleus Accumbens Shell of Male and Female Mice
  5. Are There Prevalent Sex Differences in Psychostimulant Use Disorder? A Focus on the Potential Therapeutic Efficacy of Atypical Dopamine Uptake Inhibitors
  6. Interactions of calmodulin kinase II with the dopamine transporter facilitate cocaine-induced enhancement of evoked dopamine release
  7. Oxytocin receptors mediate oxytocin potentiation of methylphenidate‐induced stimulation of accumbens dopamine in rats
  8. Synaptic Zn2+ potentiates the effects of cocaine on striatal dopamine neurotransmission and behavior
  9. Elevated body fat increases amphetamine accumulation in brain: evidence from genetic and diet-induced forms of adiposity
  10. Psychostimulant Use Disorder, an Unmet Therapeutic Goal: Can Modafinil Narrow the Gap?
  11. Modafinil and its structural analogs as atypical dopamine uptake inhibitors and potential medications for psychostimulant use disorder
  12. Cocaine-induced locomotor stimulation involves autophagic degradation of the dopamine transporter
  13. Structure-activity relationships for a series of (Bis(4-fluorophenyl)methyl)sulfinylethyl-aminopiperidines and -piperidine amines at the dopamine transporter: Bioisosteric replacement of the piperazine improves metabolic stability
  14. Increased amphetamine-induced hyperactivity intranslin (Tsn)KO mice is driven by elevated adiposity
  15. Synaptic Zn2+potentiates the effects of cocaine on striatal dopamine neurotransmission and behavior
  16. Modafinil potentiates cocaine self-administration by a dopamine-independent mechanism: possible involvement of gap junctions
  17. A further assessment of a role for Toll-like receptor 4 in the reinforcing and reinstating effects of opioids
  18. Structure–Activity Relationships for a Series of (Bis(4-fluorophenyl)methyl)sulfinyl Alkyl Alicyclic Amines at the Dopamine Transporter: Functionalizing the Terminal Nitrogen Affects Affinity, Selectivity, and Metabolic Stability
  19. Effect of systemically administered oxytocin on dose response for methylphenidate self‐administration and mesolimbic dopamine levels
  20. Translating the atypical dopamine uptake inhibitor hypothesis toward therapeutics for treatment of psychostimulant use disorders
  21. Effects of (R)-Modafinil and Modafinil Analogues on Dopamine Dynamics Assessed by Voltammetry and Microdialysis in the Mouse Nucleus Accumbens Shell
  22. Distinct effects of (R )-modafinil and its (R )- and (S )-fluoro-analogs on mesolimbic extracellular dopamine assessed by voltammetry and microdialysis in rats
  23. Pharmacological classification of centrally acting drugs using EEG in freely moving rats: an old tool to identify new atypical dopamine uptake inhibitors
  24. New Perspectives on the Use of Cannabis in the Treatment of Psychiatric Disorders
  25. Astrocytic Mechanisms Involving Kynurenic Acid Control Δ9-Tetrahydrocannabinol-Induced Increases in Glutamate Release in Brain Reward-Processing Areas
  26. Brain activity of anandamide: a rewarding bliss?
  27. Atypical dopamine transporter inhibitors attenuate compulsive-like methamphetamine self-administration in rats
  28. The Novel Modafinil Analog, JJC8-016, as a Potential Cocaine Abuse Pharmacotherapeutic
  29. Key role of the dopamine D4receptor in the modulation of corticostriatal glutamatergic neurotransmission
  30. Oxytocin’s Effects in Cocaine and Other Psychostimulant Addictions
  31. Rapid and sustained antidepressant properties of an NMDA antagonist/monoamine reuptake inhibitor identified via transporter-based virtual screening
  32. The unique psychostimulant profile of (±)-modafinil: investigation of behavioral and neurochemical effects in mice
  33. Lack of Specific Involvement of (+)-Naloxone and (+)-Naltrexone on the Reinforcing and Neurochemical Effects of Cocaine and Opioids
  34. Preclinical studies on the reinforcing effects of cannabinoids. A tribute to the scientific research of Dr. Steve Goldberg
  35. Targeting the Oxytocin System to Treat Addictive Disorders: Rationale and Progress to Date
  36. (±)-Modafinil potentiates cocaine self-administration but not the effects on DA levels in rodents
  37. Preference for Distinct Functional Conformations of the Dopamine Transporter Alters the Relationship between Subjective Effects of Cocaine and Stimulation of Mesolimbic Dopamine
  38. A systematic microdialysis study of dopamine transmission in the accumbens shell/core and prefrontal cortex after acute antipsychotics
  39. Effect of yohimbine on reinstatement of operant responding in rats is dependent on cue contingency but not food reward history
  40. Preclinical Efficacy of N-Substituted Benztropine Analogs as Antagonists of Methamphetamine Self-Administration in Rats
  41. Reducing cannabinoid abuse and preventing relapse by enhancing endogenous brain levels of kynurenic acid
  42. The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders
  43. Cocaine-induced endocannabinoid release modulates behavioral and neurochemical sensitization in mice
  44. Stimulants as Specific Inducers of Dopamine-Independent σ Agonist Self-Administration in Rats
  45. β-Arrestin 2 knockout mice exhibit sensitized dopamine release and increased reward in response to a low dose of alcohol
  46. Relations between stimulation of mesolimbic dopamine and place conditioning in rats produced by cocaine or drugs that are tolerant to dopamine transporter conformational change
  47. Self-Administration of Cocaine Induces Dopamine-Independent Self-Administration of Sigma Agonists
  48. R-Modafinil (Armodafinil): A Unique Dopamine Uptake Inhibitor and Potential Medication for Psychostimulant Abuse
  49. Peroxisome Proliferator-Activated Nuclear Receptors and Drug Addiction
  50. Lack of cocaine-like discriminative-stimulus effects of σ-receptor agonists in rats
  51. Decreases in Cocaine Self-Administration with Dual Inhibition of the Dopamine Transporter and σ Receptors
  52. A Role for Sigma Receptors in Stimulant Self Administration and Addiction
  53. Blockade of Nicotine Reward and Reinstatement by Activation of Alpha-Type Peroxisome Proliferator-Activated Receptors
  54. Sigma Receptor Agonists: Receptor Binding and Effects on Mesolimbic Dopamine Neurotransmission Assessed by Microdialysis
  55. Dopaminergic augmentation of delta-9-tetrahydrocannabinol (THC) discrimination: possible involvement of D2-induced formation of anandamide
  56. Reinforcing Effects of σ-Receptor Agonists in Rats Trained to Self-Administer Cocaine
  57. Combinations of Cocaine with Other Dopamine Uptake Inhibitors: Assessment of Additivity
  58. Fatty acid amide hydrolase (FAAH) inhibition enhances memory acquisition through activation of PPAR-  nuclear receptors
  59. Discovery of Drugs to Treat Cocaine Dependence: Behavioral and Neurochemical Effects of Atypical Dopamine Transport Inhibitors
  60. Potential Use of Opioid Antagonists in the Treatment of Marijuana Abuse and Dependence
  61. The Endocannabinoid System: A New Molecular Target for the Treatment of Tobacco Addiction
  62. Inhibition of Anandamide Hydrolysis by Cyclohexyl Carbamic Acid 3′-Carbamoyl-3-yl Ester (URB597) Reverses Abuse-Related Behavioral and Neurochemical Effects of Nicotine in Rats
  63. Cocaine‐like neurochemical effects of antihistaminic medications
  64. Cocaine-Like Neurochemical Effects of Antihistaminic Medications
  65. Blockade of THC-Seeking Behavior and Relapse in Monkeys by the Cannabinoid CB1-Receptor Antagonist Rimonabant
  66. The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition
  67. Brain-Derived Neurotrophic Factor Prevents Human Immunodeficiency Virus Type 1 Protein gp120 Neurotoxicity in the Rat Nigrostriatal System
  68. Modulation of the endocannabinoid system: Therapeutic potential against cocaine dependence
  69. Muscarinic preferential M1 receptor antagonists enhance the discriminative-stimulus effects of cocaine in rats
  70. Brain-derived neurotrophic factor expression in the substantia nigra does not change after lesions of dopaminergic neurons
  71. Nicotinic  7 Receptors as a New Target for Treatment of Cannabis Abuse
  72. Nicotinic Facilitation of Δ9-Tetrahydrocannabinol Discrimination Involves Endogenous Anandamide
  73. Effects of Muscarinic M1 Receptor Blockade on Cocaine-Induced Elevations of Brain Dopamine Levels and Locomotor Behavior in Rats
  74. The Endogenous Cannabinoid Anandamide Produces δ-9-Tetrahydrocannabinol-Like Discriminative and Neurochemical Effects That Are Enhanced by Inhibition of Fatty Acid Amide Hydrolase but Not by Inhibition of Anandamide Transport
  75. Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats
  76. Metabolic Transformation Plays a Primary Role in the Psychostimulant-Like Discriminative-Stimulus Effects of Selegiline [(R)-(–)-Deprenyl]
  77. The Endogenous Cannabinoid Anandamide and Its Synthetic Analog R(+)-Methanandamide Are Intravenously Self-Administered by Squirrel Monkeys
  78. Self-administration of cannabinoids by experimental animals and human marijuana smokers
  79. Cannabinoid Agonists but not Inhibitors of Endogenous Cannabinoid Transport or Metabolism Enhance the Reinforcing Efficacy of Heroin in Rats
  80. Effects of 4′-Chloro-3α-(diphenylmethoxy)-tropane on Mesostriatal, Mesocortical, and Mesolimbic Dopamine Transmission: Comparison with Effects of Cocaine
  81. The opioid antagonist naltrexone reduces the reinforcing effects of ? 9 -tetrahydrocannabinol (THC) in squirrel monkeys
  82. Histamine H3 Receptor Antagonists Potentiate Methamphetamine Self-Administration and Methamphetamine-Induced Accumbal Dopamine Release
  83. Cannabinoids: reward, dependence, and underlying neurochemical mechanisms?a review of recent preclinical data
  84. Self-administration of ?9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys
  85. Differential Effects of Caffeine on Dopamine and Acetylcholine Transmission in Brain Areas of Drug-naive and Caffeine-pretreated Rats
  86. Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys
  87. Alteration of the Behavioral Effects of Nicotine by Chronic Caffeine Exposure
  88. Reciprocal changes in prefrontal and limbic dopamine responsiveness to aversive and rewarding stimuli after chronic mild stress: implications for the psychobiology of depression
  89. Reduced dopamine in peripheral blood lymphocytes in Parkinsonʼs disease
  90. Dependence of mesolimbic dopamine transmission on Δ9-tetrahydrocannabinol
  91. Drug Addiction as a Disorder of Associative Learning: Role of Nucleus Accumbens Shell/Extended Amygdala Dopamine
  92. A dopamine‐μ1 opioid link in the rat ventral tegmentum shared by palatable food (Fonzies) and non‐psychostimulant drugs of abuse
  93. Blunting of reactivity of dopamine transmission to palatable food: a biochemical marker of anhedonia in the CMS model?
  94. Contribution of Blockade of the Noradrenaline Carrier to the Increase of Extracellular Dopamine in the Rat Prefrontal Cortex by Amphetamine and Cocaine
  95. Cannabinoid and Heroin Activation of Mesolimbic Dopamine Transmission by a Common µ1 Opioid Receptor Mechanism
  96. Homologies and Differences in the Action of Drugs of Abuse and a Conventional Reinforcer (Food) on Dopamine Transmission: An Interpretative Framework of the Mechanism of Drug Dependence
  97. Estimation of in-vivo neurotransmitter release by brain microdialysis
  98. Erratum: Non-psychostimulant drugs of abuse and anxiogenic drugs activate with differential selectivity dopamine transmission in the nucleus accumbens and in the medial prefrontal cortex of the rat
  99. Non-psychostimulant drugs of abuse and anxiogenic drugs activate with differential selectivity dopamine transmission in the nucleus accumbens and in the medial prefrontal cortex of the rat
  100. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs
  101. Chronic desipramine and fluoxetine differentially affect extracellular dopamine in the rat prefrontal cortex
  102. Non-psychostimulant drugs of abuse and anxiogenic drugs activate with differential selectivity dopamine transmission in the nucleus accumbens and in the medial prefrontal cortex of the rat
  103. THE MATURATION OF A CROSS-SPECIES MODEL OF SENSORIMOTOR GATING DEFICITS IN SCHIZOPHRENIA
  104. A COMPARISON OF BEHAVIOURAL EFFECTS OF RO 19???8022 AND NITRAZEPAM IN MICE
  105. Ethanol as a neurochemical surrogate of conventional reinforcers: The dopamine-opioid link
  106. Mianserin markedly and selectively increases extracellular dopamine in the prefrontal cortex as compared to the nucleus accumbens of the rat
  107. Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the "shell" as compared with the "core" of the rat nucleus accumbens.
  108. Increase of extracellular dopamine in the medial prefrontal cortex during spontaneous and naloxone-precipitated opiate abstinence
  109. Local 5HT3 receptors mediate fluoxetine but not desipramine-induced increase of extracellular dopamine in the prefrontal cortex
  110. Effect of repeated administration of antidepressant drugs on dopamine transmission in the rat prefrontal cortex
  111. Intravenous administration of psychostimulants preferentially increases dopamine release in the shell of the rat nucleus accumbens
  112. Anxiogenic drugs and drugs of abuse differentially influence limbic versus cortical dopamine transmission
  113. Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential?
  114. On the preferential release of dopamine in the nucleus accumbens by amphetamine: further evidence obtained by vertically implanted concentric dialysis probes
  115. ON THE PREFERENTIAL EFFECT OF AMPHETAMINE IN THE MESOLIMBIC SYSTEM
  116. Stimulation of dopamine transmission in the dorsal caudate nucleus by pargyline as demonstrated by dopamine and acetylcholine microdialysis and Fos immunohistochemistry
  117. Extracellular Striatal Concentrations of Endogenous 3,4‐Dihydroxyphenylalanine in the Absence of a Decarboxylase Inhibitor: A Dynamic Index of Dopamine Synthesis In Vivo
  118. Combined Microdialysis and Fos Immunohistochemistry for the Estimation of Dopamine Neurotransmission in the Rat Caudate-Putamen
  119. Blockade of the Noradrenaline Carrier Increases Extracellular Dopamine Concentrations in the Prefrontal Cortex: Evidence that Dopamine Is Taken up In Vivo by Noradrenergic Terminals
  120. Calcium-Dependent, Tetrodotoxin-Sensitive Stimulation of Cortical Serotonin Release After a Tryptophan Load
  121. Effect of temperature and ionic environment on the specific binding of 3H(—)sulpiride to membranes from different rat brain regions